SG10202101918RA - Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction - Google Patents

Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction

Info

Publication number
SG10202101918RA
SG10202101918RA SG10202101918RA SG10202101918RA SG10202101918RA SG 10202101918R A SG10202101918R A SG 10202101918RA SG 10202101918R A SG10202101918R A SG 10202101918RA SG 10202101918R A SG10202101918R A SG 10202101918RA SG 10202101918R A SG10202101918R A SG 10202101918RA
Authority
SG
Singapore
Prior art keywords
selenium
disease
prevention
compositions
treatment
Prior art date
Application number
SG10202101918RA
Other languages
English (en)
Inventor
Ronan Power
Casey Egan
Alexander Yiannikouris
Zi-Jian Lan
Rijin Xiao
Lewis Jackson
Stefan Kwiatkowski
Original Assignee
Alltech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltech Inc filed Critical Alltech Inc
Publication of SG10202101918RA publication Critical patent/SG10202101918RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG10202101918RA 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction SG10202101918RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361788133P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
SG10202101918RA true SG10202101918RA (en) 2021-03-30

Family

ID=51537786

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202101918RA SG10202101918RA (en) 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
SG11201507061XA SG11201507061XA (en) 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201507061XA SG11201507061XA (en) 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction

Country Status (15)

Country Link
US (1) US9833486B2 (https=)
EP (1) EP2968404A4 (https=)
JP (1) JP6313418B2 (https=)
KR (1) KR102245702B1 (https=)
CN (3) CN114533753A (https=)
AU (1) AU2014228785B2 (https=)
BR (1) BR112015022514A2 (https=)
CA (1) CA2903845C (https=)
CL (1) CL2015002677A1 (https=)
HK (1) HK1216506A1 (https=)
MX (1) MX359626B (https=)
RU (1) RU2663127C2 (https=)
SG (2) SG10202101918RA (https=)
WO (1) WO2014144776A1 (https=)
ZA (1) ZA201506759B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX384232B (es) 2013-03-14 2025-03-14 Jerome J Schentag Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones.
RU2665135C2 (ru) * 2014-03-14 2018-08-28 Олтек, Инк. Композиции селеноорганических соединений и способы их применения
WO2016160594A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
WO2017160678A1 (en) * 2016-03-14 2017-09-21 Mitogenetics, Llc Materials and methods for treating hypoxic conditions
AU2018269403B2 (en) 2017-05-19 2025-03-27 Alltech, Inc. Pharmaceutical agents, compositions, and methods relating thereto
JP7250810B2 (ja) * 2018-04-25 2023-04-03 オンコクロス カンパニー,リミテッド 筋肉疾患の予防及び治療用組成物
CN108283711A (zh) * 2018-05-06 2018-07-17 冷立娟 一种治疗酒精性心肌病的中药冲剂及其制备方法
CN109820933A (zh) * 2019-02-27 2019-05-31 北京曲佳科技有限公司 减肥片及其制备方法
CN111493325A (zh) * 2020-05-07 2020-08-07 恩施德源健康科技发展有限公司 植物硒肽在制备改善肥胖及代谢综合征组合物中的应用
US20230129707A1 (en) * 2020-06-29 2023-04-27 Bristol-Myers Squibb Company Automated system and method for analyzing samples from a bioreactor
CN112129864B (zh) * 2020-09-24 2022-04-01 江南大学 一种富硒植物干粉中硒形态测定的方法
KR102328808B1 (ko) * 2020-12-02 2021-11-22 동의대학교 산학협력단 맥주효모를 이용한 근감소증 예방 및 개선용 조성물
CN114053298A (zh) * 2021-11-19 2022-02-18 华中农业大学 一种用于抑制心肌肥大的药物及模型的构建方法
CN114235989A (zh) * 2021-11-27 2022-03-25 山东省烟台市农业科学研究院 一种测定福美甲胂含量的高效液相色谱法
CN114031650B (zh) * 2021-11-29 2023-05-02 上海交通大学 壳寡糖硒配位化合物及其制备方法和应用
CN114924001B (zh) * 2022-05-12 2024-11-19 中国计量科学研究院 一种基于独立校准的含磷或含硒化合物标准溶液定值方法
CN114931569B (zh) * 2022-06-22 2023-05-16 中国农业科学院油料作物研究所 甲基硒代半胱氨酸在制备提高雄性生殖能力的产品中的应用
CN116333302B (zh) * 2023-03-31 2024-09-10 中南大学 一种稳定持久抗氧化纳米点及其在二型糖尿病中的应用
CN116421618B (zh) * 2023-06-15 2023-09-29 暨南大学 Se@NADH的制备方法及其在脊髓损伤治疗中的应用
CN120531844A (zh) * 2025-07-02 2025-08-26 内蒙古肽元生物科技有限公司 生物活性肽在增强哺乳动物卵母细胞成熟及胚胎发育潜能中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5896024A (ja) * 1981-10-16 1983-06-07 リチヤ−ド・エフ・ストツケル 白金毒解毒剤
US5221545A (en) 1992-03-09 1993-06-22 Abbott Laboratories Method of providing selenium in a nutritional product
US6197295B1 (en) 1996-09-25 2001-03-06 Viva America Marketing Corporation Dietary supplementation with, and methods for administration of yeast-derived selenium product
US6911550B2 (en) 2003-02-21 2005-06-28 Zinpro Corporation Derivatives of seleno-amino acids with improved bioavailability and method for their preparation
OA13177A (en) * 2003-06-04 2006-12-13 Willem Jacob Serfontein Nutritional compositions and use thereof.
PL214402B1 (pl) * 2003-08-11 2013-07-31 Tomasz Byrski Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika
US20050069594A1 (en) 2003-08-11 2005-03-31 Jan Lubinski Pharmaceutical compositions and methods for the prevention of breast and ovarian cancer
WO2005023274A1 (en) * 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
US8871715B2 (en) * 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
TWI319708B (en) * 2005-10-14 2010-01-21 Methods and compositions for altering cell fuction
US20100247679A1 (en) * 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
US8846111B2 (en) * 2007-05-18 2014-09-30 Alltech, Inc. Compositions and methods for establishing and/or maintaining pregnancy
WO2009018492A2 (en) * 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
WO2009032057A2 (en) * 2007-08-29 2009-03-12 Adam Lubin Method for the selective therapy of disease
ES2378595T3 (es) * 2007-10-16 2012-04-16 Actigenomics S.A. Composición destinada a la regulación del metabolismo de los lípidos
CN101579355B (zh) * 2009-05-27 2010-12-08 徐建兴 一种维护线粒体功能的营养组合物及其应用
EP3095458B1 (en) * 2009-10-22 2018-07-25 Propanc Pty Ltd Pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen
US8575320B2 (en) 2010-03-18 2013-11-05 Alltech, Inc. Compositions and methods for separating, characterizing and administering soluble selenoglycoproteins
WO2011132799A1 (en) * 2010-04-22 2011-10-27 Kyoto University Method for inducing differentiation of pluripotent stem cells into skeletal muscle or skeletal muscle progenitor cells
KR20120048205A (ko) * 2010-11-05 2012-05-15 한국식품연구원 메틸셀레노시스테인을 유효성분으로 함유하는 비만 및 지질 관련 대사성 질환의 예방 및 치료용 조성물
EP2705844B1 (en) 2011-04-13 2019-05-22 Ajinomoto Co., Inc. Nutritional composition

Also Published As

Publication number Publication date
KR102245702B1 (ko) 2021-04-28
MX359626B (es) 2018-10-01
SG11201507061XA (en) 2015-10-29
US9833486B2 (en) 2017-12-05
US20160113977A1 (en) 2016-04-28
EP2968404A4 (en) 2017-01-04
JP6313418B2 (ja) 2018-04-18
JP2016516058A (ja) 2016-06-02
AU2014228785B2 (en) 2018-01-25
CA2903845A1 (en) 2014-09-18
KR20150132374A (ko) 2015-11-25
AU2014228785A1 (en) 2015-09-24
RU2663127C2 (ru) 2018-08-01
EP2968404A1 (en) 2016-01-20
RU2015139742A (ru) 2017-04-21
BR112015022514A2 (pt) 2017-07-18
CL2015002677A1 (es) 2016-12-09
MX2015013275A (es) 2015-12-11
CN114984038A (zh) 2022-09-02
CA2903845C (en) 2022-08-23
NZ711842A (en) 2021-04-30
HK1216506A1 (zh) 2016-11-18
CN114533753A (zh) 2022-05-27
ZA201506759B (en) 2017-03-29
CN105377271A (zh) 2016-03-02
WO2014144776A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
ZA201506759B (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
IL273688A (en) Evaluation and treatment of bradykinin-mediated disorders
IL256624B (en) Pharmaceutical compounds and preparations thereof for the treatment of inflammatory disorders
IL242483B (en) Preparations containing omomyc and their use for cancer treatment
SG10201710473VA (en) Combination of vaccination and inhibition of the pd-1 pathway
PL2991507T3 (pl) Zastosowanie kompozycji zawierającej olej rybny i sok do leczenia i/lub po leczeniu nowotworu
IL261431B (en) Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use
IL244621A (en) Preparations for the treatment of hypertension and / or fibrosis
IL244622A0 (en) Preparations for the treatment of hypertension and/or fibrosis
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
IL246587A0 (en) Preparations for use in the treatment of allergic conditions
IL245998A0 (en) Pharmaceutical preparations and a method for the treatment of metastatic cancer and its prevention
PL3041459T3 (pl) Kompozycje przydatne w zapobieganiu lub leczeniu raka skóry
IL259383A (en) A compound for use in the prevention and treatment of neurodegenerative diseases
PL2862576T3 (pl) Drobnoustroje i zawierające je kompozycje do stosowania do leczenia lub profilaktyki zapalenia sutka
GB201316698D0 (en) Use of tri-substituted glycerol compounds for prevention and treatment of allo-immune disorders